The Series B extension brings Atavistik Bio’s Series B financing to $160 million. The startup’s lead program is in development for hereditary hemorrhagic telangiectasia (HHT), an inherited bleeding disorder.
The post Startup Atavistik Adds $40M for Clinical Trial in Rare Bleeding Disorder With No Approved Therapies appeared first on MedCity News.
